Introduction
Non-Hodgkin's lymphoma (NHL) is a heterogeneous group of disorders that represents about 4% of all malignancies and ranks fifth in cancer incidence and mortality. Although the initial response rates to chemotherapy are high, relapses eventually occur and subsequent chemotherapy regimens are incapable of yielding long-term remission (Rogers, 2006) . One of the candidate antigens that has been targeted for immunotherapy is CD20, a 297-amino-acid (32-37 kDa) unglycosylated phosphoprotein that spans the membrane four times (Ernst et al., 2005) . CD20 is expressed specifically within the B-cell lineage from pre-B cells to mature B cells. Rituximab (chimeric antihuman CD20 antibody) mediates its antitumor activity by multiple mechanisms that include complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity and induction of apoptosis following CD20 cross-linking (Shan et al., 1998; . We have recently reported that rituximab sensitizes drugresistant B-NHL cell lines to the apoptotic effects of various chemotherapeutic drugs via the selective downregulation of Bcl-xL expression. Downregulation of Bcl-xL expression was the result of inhibition of both the Raf/MEK/ERK1/2 and NF-kB survival pathways (Jazirehi et al., 2004 .
Akt is a serine/threonine protein kinase that mediates various downstream effects of PI3-K. It plays a central role in signaling by the PI3-K pathway by regulating many biological processes, such as proliferation, apoptosis and cell growth (Cantley et al., 2002) . In addition, the activated PI3K-Akt pathway provides major survival signals to lymphoma cells and many other cancer cells (Goswami et al., 2006; Toker and Yoeli-Lerner, 2006) . Akt controls a variety of mechanisms that inhibit apoptosis and prolong cell survival, exerting a positive effect on NF-kB functions (Ozes et al., 1999; Osaki et al., 2004) .
The Akt pathway is constitutively activated in most tumor cells and in B-NHL cell lines and in B-NHL derived from patients (Arranz et al., 1996) . Bcl-xL expression and/or activity can be regulated by the Akt pathway (Uddin et al., 2004) . The regulation by the PI3k pathway of Bcl-xL activity results from Akt-mediated phosphorylation (p) of Bad, and thus promoting p-Bad to interact with Bcl-xL and forming heterodimeric complexes. The regulation of Bcl-xL translation and transcription by the Akt pathway is indirect and under the control of NF-kB, and NF-kB is regulated by the Akt pathway (Cuni et al., 2004) . Because our prior findings demonstrated that rituximab inhibits Bcl-xL expression via inhibition of both the ERK1/2 and NF-kB pathways (Jazirehi et al., 2004 , we hypothesized that downregulation of Bcl-xL expression by rituximab may also involve the Akt pathway. Thus, as Bcl-xL regulates chemoresistance, we hypothesized that inhibition of the Akt pathway and Bcl-xL by rituximab could contribute to the sensitization of tumor cells to chemotherapy-induced apoptosis. This hypothesis was tested with B-NHL cell lines and the followings were investigated: (1) Does rituximab inhibit the Akt signaling pathway? (2) Does rituximab inhibit the phosphorylation of Bad and augment the complex formation between Bcl-xL and Bad? (3) Does inhibition of the Akt pathway inhibit Bcl-xL activity and expression? (4) Does the direct inhibition of the Akt pathway by siRNA Akt or a pharmacologic Akt inhibitor, Ly294002, mimic rituximab and sensitizes B-NHL cells to apoptosis by chemotherapeutic drugs? and (5) Does rituximab failure to sensitize rituximab-resistant clones can be reversed by Ly294002? The findings obtained were concordant with the above hypotheses.
Results
Rituximab diminishes the constitutive activity of the PI3k-Akt signaling pathway in B-NHL cells We have recently reported that rituximab treatment of B-NHL cell lines resulted in inhibition of the survival Raf-1/MEK/ERK1/2 and the NF-kB signaling pathways both of which led to the selective inhibition of the expression of the anti-apoptotic gene product Bcl-xL (Jazirehi et al., 2004 . Hence, we explored if other signaling pathways that also regulate Bcl-xL expression and/or activity may also be inhibited by rituximab. The Akt pathway has been shown to regulate Bcl-xL transcriptional and post-transcriptional expression and activity (Hayakawa et al., 2000; Weintraub et al., 2004) . Hence, we examined whether rituximab treatment inhibits the activity of the Akt pathway. Time kinetic analyses revealed that rituximab treatment of Ramos inhibited phospho(p)-Lyn (Tyr507), phosphorylation of Akt (p-Akt) (Ser473 and Thre308), p-PDK1 and p-Bad, although there was no detectable inhibition of nonphosphorylated proteins. The inhibition was first observed at 6 h post-rituximab treatment and was maintained up to 24 h (Figure 1a) . The rituximabmediated inhibition of p-Akt was direct as treatment of Ramos with Fc-devoid rituximab (Fab)' 2 also inhibited p-Akt like rituximab (Figure 1b) . The PI3K-Akt signaling pathway regulates the transcriptional expression of Bcl-xL via IkappaB kinase (IKK), IkB and NF-kB activation (Sugimori et al., 2005) and, thus, we expected that rituximab treatment of Ramos would also inhibit the phosphorylation of these gene products. Treatment of Ramos cells with rituximab diminished the levels of p-IKKa/b and p-Ikba, but not the levels of nonphosphorylated proteins, and the inhibition was first detected at 6 h post-rituximab treatment and significant inhibition was observed after 24 h (Figure 1c ). The level of IkBa was augmented 3 h following rituximab treatment as less degradation takes place. The findings above demonstrate that rituximab treatment of Ramos cells inhibits the constitutively activated Akt and NF-kB pathways in a time-dependent fashion as early as 6 h post-treatment.
The Akt signaling pathway regulates Bcl-xL activity via phosphorylation of Bad, which normally dissociates from Bcl-xL , and dissociated Bcl-xL can thus exert its anti-apoptotic activity. Likewise, phosphorylation of Bad also promotes cell survival (Datta et al., 1999; Hayakawa et al., 2000) . Therefore, we expected that treatment of Ramos with rituximab, which inhibited pBad (Figure 1a) , would significantly enhance the physical association of Bad and Bcl-xL . This was determined by treating Ramos cell lysates with antiBcl-xL antibody and the immunoprecipitated complexes (Bcl-xL -Bad) were analysed. Clearly, treatment of lysates from rituximab-treated Ramos cells showed significant augmentation of Bad in the immunoprecipitate as compared to the Bad level in untreated cell lysates (Figure 1d ). The lysates of rituximab-treated cells also contain less Bcl-xL as compared to untreated cells. These findings demonstrate that rituximab-induced inhibition of the Akt signaling pathway in Ramos cells significantly enhanced the complex formation of nonphosphorylated Bad with Bcl-xL concomitant with inhibition of Bcl-xL .
Treatment of Ramos cells with the Akt inhibitor LY294002 mimics rituximab-mediated inhibition of the Akt pathway We examined the direct role of the Akt pathway in the regulation of Bcl-xL expression in Ramos cells using the Akt specific inhibitor, LY294002. Treatment of Ramos cells with LY294002 inhibited the Akt pathway beginning at 6 h post-treatment. There was inhibition of p-Akt (Ser473), p-Akt (Thr308), p-PDK1 and p-Bad in the absence of any inhibition of non-phosphorylated proteins ( Figure 2a ). In addition, treatment of Ramos cells with LY294002 inhibited Bcl-xL expression like rituximab (Figure 2b ). Altogether, these findings suggest that rituximab-induced inhibition of the Akt pathway participates in the inhibition of Bcl-xL expression.
Participation of rituximab-mediated inhibition of the Akt pathway in the chemosensitization of B-NHL cells to drug-induced apoptosis Two approaches were examined to determine the role of the AKT pathway in chemosensitization, namely, the use of a pharmacologic-specific Akt inhibitor, Ly294002 and inhibition of Akt by siRNA.
(1) Inhibition of the Akt pathway by LY294002 mimics rituximab-mediated sensitization of Ramos and Daudi cells to drug-induced apoptosis.
Rituximab treatment of Ramos cells for 24 h significantly sensitized the cells to cis-platinum (CDDP)-induced apoptosis, and the sensitization was a function of the antibody concentration used. Treatment with single agent had no cytotoxic activity ( Figure 3a Rituximab-mediated inhibition of the PI3k-Akt pathway E Suzuki et al with rituximab, treatment of Ramos cells with various concentrations of LY294002 (10-30 mM) also sensitized Ramos cells to CDDP-induced apoptosis, and the sensitization was a function of the LY294002 concentration used (Figure 3d ). Similar findings were also observed with cells treated with LY294002 for adriamycin (ADR)-induced apoptosis (Figure 3e ). These findings demonstrate that the inhibition of the Akt pathway by rituximab participates in the sensitization of B-NHL cells to drug-induced apoptosis.
We have recently reported that rituximab resistant Ramos (RR) and Daudi (RR) clones, generated in our laboratory, did not respond to rituximab-induced signaling and, further, rituximab did not chemosensitize the cells to drug-induced apoptosis (Jazirehi et al., 2007) . Thus, we examined whether rituximab treatment affects the Akt pathway in Ramos RR1 cells. There was no inhibition of p-Akt (Ser473) by rituximab in Ramos RR1 (Figure 4a , top) or chemosensitization to CDDP (Figure 4a , Bottom). However, treatment of Ramos RR1 with LY294002 significantly sensitized the Ramos RR1 cells to CDDP-induced apoptosis (Figure 4b ). These findings demonstrate that rituximab resistance can be overcome by an inhibitor of the Akt pathway.
(2) Inhibition of the Akt pathway by Akt siRNA sensitized Ramos and Ramos RR1 cells to CDDPinduced apoptosis.
The direct role of the Akt pathway in the regulation of drug resistance was tested by transfecting Ramos cells with Akt siRNA as described in methods. Treatment of Ramos cells with Akt siRNA resulted in significant inhibition of p-Akt and Akt beginning at 48 h posttransfection. There was also concomitant inhibition of Bcl-xL expression. However, transfection with control siRNA had no detectable effect (Figure 5a , top). Treatment with Akt siRNA, but not with siRNA control, significantly sensitized the cells to CDDPinduced apoptosis and 5 mg Akt SiRNA was optimal (Figure 5a , bottom). The findings with Akt siRNA corroborated with the findings above with LY294002. Like with wild-type Ramos, treatment of Ramos RR1 with Akt siRNA inhibited p-Akt (Ser473) and Akt (Figure 5b, top) and sensitized the cells to CDDPinduced apoptosis (Figure 5b, bottom) .
Altogether, the above findings demonstrate that rituximab-induced inhibition of the Akt pathway contributes to rituximab-mediated chemosensitization in both wild-type and resistant clones.
Discussion
The present findings demonstrate for the first time that treatment of B-NHL cell lines with rituximab significantly inhibited the constitutively activated PI3k-Akt signaling pathway. Inhibition of this pathway resulted in inhibition of both Bcl-xL activity and Bcl-xL expression. The role of the Akt pathway in rituximab-induced sensitization of drug-resistant B-NHL cells to apoptosis by chemotherapeutic drugs was corroborated by the use of both the PI3K inhibitor Ly294002 and by the use of silencer RNA for Akt. Treatment of Ramos RR1 with LY294002 or Akt SiRNA inhibited the Akt pathway and Bcl-xL expression, and sensitized the cells to drug-induced apoptosis. These findings established the involvement of the activated Akt pathway in the regulation of chemoresistance in B-NHL. Further, inhibitors of the Akt pathway sensitized both rituximab-sensitive and rituximab-resistant tumor cells. Further, the findings identify the Akt pathway as a potential novel target for therapeutic intervention in the treatment of rituximab and drug-resistant B-NHL when used alone or in combination with cytotoxic drugs.
Aberrant activation of the PI3K-Akt pathway has been widely implicated in many cancers. The PI3K-Akt signaling pathway regulates many normal cellular processes (Vivanco and Sawyers, 2002) . The PI3K-Akt pathway is a key regulator of cell survival through multiple downstream targets. Ramos, Daudi and Ramos RR1 cells exhibit constitutively activated signaling of the Akt pathway. Rituximab treatment inhibited both pAkt (ser473) and p-Akt (Thr308) as early as 6 h. The inhibition of pPDK1 and p-Bad by rituximab followed the same time kinetics as those for Akt. Akt can phosphorylate the Bcl-2 family member Bad, causing its sequestration from the mitochondrial membrane by 14-3-3 protein (Datta et al., 1999) . In its unphosphorylated form, Bad binds to and inactivates anti-apoptotic proteins, such as Bcl-2 and Bcl-xL , leading to its proapoptotic function. Inhibition of pBad was initially observed at 6 h post-rituximab treatment. The inhibition of pBad in Ramos cells resulted in the augmented association of Bad with Bcl-xL to form more complexes. Complexes of Bad and Bcl-2 could not be detected in Ramos as these cells are deficient in Bcl-2 expression, and we have previously confirmed this finding (Jazirehi et al., 2004) .
A cross talk between the PI3K and the NFkB pathway has been reported previously in a number of systems (Yin et al., 2006) . Treatment with rituximab inhibited the phosphorylation of IKK and IkBa, indicating that rituximab inhibits the anti-apoptotic effect regulated by NFkB. Considerable controversy remains regarding the involvement of Akt in signalinduced IKK activation. Thus, it is possible that Akt phosphorylates IKK in a cell context and stimulationdependent manner.
Previous findings demonstrated the roles of the Raf/ ERK1/2 and NF-kB pathways in rituximab-induced sensitization to apoptosis by chemotherapeutic drugs Jazirehi et al., 2004 . The direct role of the activated Akt pathway in the regulation of resistance was independently demonstrated by the use of LY294002 and siRNA. Both inhibited Bcl-xL expression and sensitized the tumor cells to drug-induced apoptosis. Ly294002 has long been used as a selective inhibitor of PI3K-mediated p-Akt (Poh and Pervaiz, 2005) . The chemosensitization induced by LY294002 resembles that induced by rituximab with similar time kinetics as those observed with rituximab. These findings support the contribution of rituximab-induced inhibition of the Akt pathway in chemosensitization. Our present findings are consistent with other studies that have been reported with the use of LY294002 (Wetzker and Rommel, 2004 ).
We also demonstrate that rituximab-resistant Ramos RR1 cells were sensitized by LY294002 to drug-induced apoptosis. LY294002 inhibited the constitutive activity of p-Akt and Bcl-xL expression (Figure 4b ). This finding is of potential therapeutic application in the treatment of drug and rituximab-resistant tumor cells by combination of Akt inhibitors and cytotoxic drugs. In addition to the role of LY294002 as an inhibitor, we showed that (Figure 5b ). Consistent with our findings, clinically, knockdown of Akt by antisense or siRNA significantly reduced tumor cell growth and invasiveness, and induced cell growth arrest and apoptosis in tumor cells overexpressing Akt (Cheng et al., 1996) . There was a strong correlation between Bcl-xL inhibition by rituximab treatment or by Akt inhibitors (LY294002 and Akt siRNA) and chemosensitization. Thus, Bcl-xL inhibition in tumor cells is of clinical significance. Zhao et al. (2004) investigated the clinical significance of Bcl-xL expression in patients with follicular lymphoma using real-time quantitative polymerase chain reaction. A high Bcl-xL level was significantly associated with progression and with the international prognostic index indicating high risk. Moreover, Bcl-xL gene overexpression was linked to short overall survival (Zhao et al., 2004) . Bcl-xL is abundantly expressed in lymphoma (Xerri et al., 1996) and protects the cells from apoptosis induced by DNAdamaging agents.
Various mechanisms contribute to the activation of the Akt pathway in tumors, including perturbation of upstream tensin homologue deleted on chromosome 10 (PTEN) and phosphatidylinositol (3,4,5) triphosphate (PIP3) (Vivanco and Sawyers, 2002) . Others include autocrine or paracrine stimulation of receptor tyrosine kinases and overexpression of growth factor receptors and/or Ras activation. It has been shown that Akt is activated constitutively by active Ras and Src (Datta et al., 1999) . Rituximab inhibits the Src kinase pLyn (Jazirehi et al., 2004) and was confirmed here (Figure 1a) , and it is possible that this inhibition is involved in the downstream inhibition of the Akt pathway by rituximab. The PTEN tumor suppressor is a negative regulator of the Akt pathway (Di Cristofano and Pandolfi, 2000) . Targeting of Akt, directly or indirectly, inhibits cell proliferation, promotes apoptosis and/or increases sensitivity to chemotherapy (Tachiiri et al., 2000) . The loss of PTEN expression has been reported in a variety of cancers (Rennie and Nelson, 1998; Marsit et al., 2005; Haiman et al., 2006) . There are relatively a few studies exploring PTEN abnormalities in lymphoma. Preliminary findings indicated that Figure 3c were performed except that the rituximab-resistant Ramos RR1 clone was used. Shown in the top, Western blot analyses for unphosphorylated and phosphorylated Akt and b-actin was used a control for loading. The bottom figure shows the data on the failure of rituximab to sensitize Ramos RR1 cells to CDDP-induced apoptosis. (b) Ramos RR1 cells were treated with various concentrations of LY294002 (0-30 mM), and then treated with CDDP (15 mg/ml) and apoptosis was determined. Po0.005 represents the significance between the combination treatment and treatment with single agent. The above findings are representative of three independent experiments yielding similar results. Figure 3 Chemosensitization of Ramos and Ramos RR1 by rituximab, rituximab (Fab)' 2 and LY294002. (a) Ramos cells were treated with different concentrations of rituximab (0-20 mg/ml) for 20 h and then treated with CDDP (15 mg/ml) for an additional 24 h. The cells were then evaluated for apoptosis by the PI method as described in Materials and methods. Po0.001 represents the combination treatment of rituximab (20 mg/ml) and CDDP as compared to treatment with CDDP alone. Po0.005 represents the combination treatment of rituximab (15 mg/ml) þ CDDP as compared to treatment with CDDP alone. (b) Similar experiments to those described in (a) above were performed except that rituximab (Fab)' 2 (0-15 mg/ml) was used instead of rituximab. Po0.001 represents the combination of rituximab (Fab)' 2 þ CDDP as compared to treatment with CDDP alone. (c) Daudi B-NHL cells were treated with rituximab (20 mg/ml) and incubated for 0-24 h. Total cell lysates were prepared and examined for phosphor-Akt (ser 473), Akt and bactin. Apoptosis was determined by the PI/Annexin V method as described in Materials and methods. (d) Similar experiments as those described above in (a) were performed except that different concentrations of Ly294002 (0-30 mM) were used instead of rituximab. Po0.005 represents the combination of LY294002 (20 and 30 mM) and CDDP as compared to treatment with CDDP alone. (e) Similar experiments as those described above in (c) were performed except that ADR (5 mg/ml) was used instead of CDDP. Po0.001 represents the combination of LY294002 (10 and 25 mM) þ ADR (5 mg/ml) as compared to treatment with ADR alone. The above experiments are representative of three different experiments with similar findings.
Rituximab-mediated inhibition of the PI3k-Akt pathway E Suzuki et al rituximab treatment of Ramos resulted in PTEN induction. The roles of PTEN induction in Ramos by rituximab, in both the regulation of the Akt pathway and chemosensitization, are currently being investigated in our laboratory.
In summary, the present findings demonstrate that rituximab inhibits the constitutively activated Akt pathway in the Ramos B-NHL cells and results in inhibition of both Bcl-xL activity and expression, leading to reversal of drug resistance. A schematic diagram summarizing the findings of this study is illustrated in Figure 6 . Our findings indicate that modulation of the PI3K-Akt pathway and components of the Akt signal transduction pathway by rituximab are responsible, in part, for chemosensitization. Blocking this pathway could impede the proliferation of tumor cells by increasing sensitivity of tumor cells to undergo apoptosis in response to other cytotoxic agents. Several inhibitors have been the subject of several investigations to intervene in the Akt pathway for tumor cell sensitization . LY294002 or Akt siRNA inhibited the Akt pathway, and like rituximab, led to chemosensitization. Thus, this study identifies the components of the Akt pathway as targets for therapeutic intervention, when used alone or in combination with therapeutics, in the treatment of drug/rituximab resistance NHL. It is speculated that hyperactivation of the Akt pathway may also be involved in the pathogenesis of NHL and the development of drug/rituximab resistance. Thus, hyperactivation of this pathway may serve as a prognostic indicator in patients who are refractory to conventional therapies.
Materials and methods
Reagents RPMI-1640, opti-MEM and fetal bovine serum (FBS) were purchased from Gibco (Grand Island, NY, USA). Rituximab (stock, 10 mg/ml) was obtained commercially. Rituximab (Fab)' 2 was a generous gift from Dr. Chin (Idec Biogen, San Diego, CA, USA). LY294002, anti-Lyn, anti-phospho Lyn (Tyr507), anti-IKKa/b, anti-Ikba/b, anti-IKKb, anti-Bcl-xL , anti-Bad, anti-phospho-Bad (Ser136), anti-phospho PDK1, antihuman phospho-Akt (Ser473, Thr308), anti-Akt and antib-actin antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA). Akt siRNA and control scramble siRNA were purchased from Sigma (MO, USA). Protein Aagarose was purchased from Pierce (Rockford, IL, USA). The Annexin V-FITC kit was purchased from Beckman Coulter (Marseille, France). The CD20 þ human Burkitt's lymphoma B-cell lines Ramos and Daudi were obtained from ATCC (Manassas, VA, USA). The Ramos RR1 clone was generated in our laboratory following culture of Ramos in the presence of increasing concentrations of rituximab for 10 weeks and clones were isolated by limiting dilution (Jazirehi et al., 2007) .
Drug pretreatment
This was done as discussed previously (Jazirehi et al., 2004) .
Analysis of apoptosis DNA fragmentation was detected by flow cytometric analysis after propidium iodide staining as described (Alas and Figure 3a -c, f and g. The PI method was performed for analyses in Figure 3d and e.
Western blotting
Analysis by Western blotting was done according to our previous studies (Jazirehi et al., 2004) . Immunoprecipitation Ramos cells (2 Â 10 6 cells) were collected and resuspended with lysis buffer (20 mM Tris-HCl (pH 8.0), 2 mM ethylenediaminetetraacetic acid, 3% NP-40, 100 mM NaCl, 50 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 1 mM VO 4 , 5 mg/ml aprotinin, 5 mg/ml leupeptin). After 30 min of incubation on ice, samples were centrifuged at 10 000 g, for 10 min at 41C to remove cellular debris. The concentration of the protein in the resulting supernatant was measured using the Bio-Rad Laboratories (Hercules, CA, USA) protein assay reagent and equalized with radioimmunoprecipitation (RIPA) buffer. One milligram of total lysate was incubated with 5 ml protein A agarose beads (Pierce, Rockford, IL, USA), centrifuged and the supernatant was collected. The supernatant was mixed with 15 ml of protein A agarose and 2 mg Bcl-xL mouse monoclonal antibody or normal mouse immunoglobulin G (IgG)-1 at 4 1C for 4 h. Following centrifugation, the beads were washed four times with RIPA buffer, and the beads were boiled in 50 ml Laemmli buffer and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and blotted with rabbit anti-Bad antibody. After overnight incubation with the primary antibody, the membranes were washed and incubated with horseradish peroxidase -coupled secondary goat anti-rabbit antibody (Cell Signaling, MA, USA). Immunoreactive bands were detected using an enhanced chemiluminescence system (Amersham Pharmacia Biotech, UK). fections were performed using Xtreme GENE reagent (Roche Diagnostics Corporation, Indianapolis, IN, USA), Akt siRNA (Sigma, MO, USA) and control scramble siRNA (Sigma, MO, USA) according to the manufacturer's instructions. To determine Akt siRNA-induced sensitization to CDDP-induced apoptosis following transfection, the cells were treated with CDDP for 24 h, then were processed for PI/Annexin V staining and analysed by flow cytometry as described above.
Statistical analysis
Assays were set up in triplicates and the results were expressed as the mean7s.d. Statistical analysis and P-value determinations were done by two-tailed paired t-test with a confidence interval of 95% for determination of the significance of differences between the treatment groups. Po0.05 was considered to be significant.
